Short Summary
AZURITY PHARMACEUTICALS successfully convinced the PTAB to institute IPR proceedings against Helsinn Healthcare S.A.'s patent covering anti-emetic agents for oncology treatment. The Board found a reasonable likelihood that numerous claims would be unpatentable under 35 U.S.C. § 103 based on prior art references.
Detailed Summary
AZURITY PHARMACEUTICALS, INC., the Petitioner, successfully obtained institution of IPR proceedings against Helsinn Healthcare S.A.'s patent (9186357) covering anti-emetic agents used in oncology treatment. The Board determined that the Petitioner demonstrated a reasonable likelihood that at least one challenged claim would be unpatentable over the prior art of record, primarily under 35 U.S.C. § 103. Key arguments centered on Herrstedt teaching a relevant triple-drug regimen and Bös providing motivation to substitute specific compounds within that regimen. The decision signals a strong challenge to the patent's validity based on obviousness in this specialized pharmaceutical field.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in AZURITY PHARMACEUTICALS, INC. vs Helsinn Healthcare S.A. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Texas Instruments IncorporatedvsGreenthread, LLC
The Director granted review in multiple IPRs involving Texas Instruments and Greenthread, vacating the FWDs. The cases are remanded to allow discovery on privity issues across related proceedings.
Samsung Electronics Co. Ltd., et al.vsMobile Data Technologies LLC
Samsung has filed a petition for Director Review after the PTAB denied institution of an IPR against Mobile Data Technologies' patent 9,619,578. The petition alleges abuse of discretion, examiner error, and violations of due process. It seeks reversal and institution of the review.
Tesla, Inc.vsIntellectual Ventures II LLC
Tesla has filed an IPR petition seeking to invalidate claims 1‑7 of U.S. Patent 6,894,639, arguing they are obvious over earlier image‑processing patents (Barnard, Knecht, Lawrence). The petition also argues that discretionary denial is unwarranted.
Nokia of America Corp.vsAdaptive Spectrum and Signal Alignment, Inc.
Nokia and Adaptive Spectrum and Signal Alignment, Inc. filed a joint motion to terminate an IPR concerning U.S. Patent 7,991,122. The PTAB granted the motion and ordered the settlement agreement to be kept confidential, ending the proceeding before trial.
Nokia of America Corp.vsADAPTIVE SPECTRUM AND SIGNAL ALIGNMENT, INC.
Nokia and Adaptive Spectrum reached a settlement, leading the PTAB to terminate the IPR before trial. The settlement agreement was ordered to be kept confidential under 37 C.F.R. § 42.74(c).
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.